These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6181872)

  • 1. Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
    Powis G
    Cancer Treat Rev; 1982 Jun; 9(2):85-124. PubMed ID: 6181872
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical pharmacokinetics of commonly used anticancer drugs.
    Balis FM; Holcenberg JS; Bleyer WA
    Clin Pharmacokinet; 1983; 8(3):202-32. PubMed ID: 6189661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of antitumor drugs].
    Filov VA; Kulik GI
    Vopr Onkol; 1983; 29(7):3-13. PubMed ID: 6410584
    [No Abstract]   [Full Text] [Related]  

  • 4. Sparfosate. A novel biomodulator of 5-fluorouracil.
    Koshland P; Maa L; Ignoffo R
    Cancer Pract; 1999; 7(4):212-6. PubMed ID: 10687588
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pharmacokinetics of antineoplastic agents (author's transl)].
    Carcassonne Y; Cano JP; Meyer G
    Bull Cancer; 1979; 66(1):39-42. PubMed ID: 311229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrations of N-(phosphonacetyl)-L-aspartate (PALA) in plasma and tears in man.
    Lankelma J; Penders PG; Leyva A; Kleeberg UR; Kenny JB; Bramwell V; McVie JG; Pinedo HM
    Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1199-204. PubMed ID: 7199467
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic drug interactions of commonly used anticancer drugs.
    Balis FM
    Clin Pharmacokinet; 1986; 11(3):223-35. PubMed ID: 2426030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of anticancer drugs in children.
    Evans WE; Crom WR; Sinkule JA; Yee GC; Stewart CF; Hutson PR
    Drug Metab Rev; 1983; 14(5):847-86. PubMed ID: 6197269
    [No Abstract]   [Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic models for anticancer drugs.
    Chen HS; Gross JF
    Cancer Chemother Pharmacol; 1979; 2(2):85-94. PubMed ID: 93986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to 5-fluorouracil modulation.
    Martin DS
    Cancer Invest; 1990; 8(2):257-8. PubMed ID: 2400944
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
    Wagner T; Heydrich D; Bartels H; Hohorst HJ
    Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical modulation of 5-fluorouracil by PALA.
    O'Dwyer PJ
    Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
    Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
    Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and disposition of Baker's antifolate (NSC-139105), ftorafur (NSC-148958), and dichloroallyl lawsone (NSC-126771) in man.
    Loo TL; Benjamin RS; Lu K; Benvenuto JA; Hall SW; McKelvey EM
    Drug Metab Rev; 1978; 8(1):137-50. PubMed ID: 363378
    [No Abstract]   [Full Text] [Related]  

  • 15. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
    Erlichman C; Strong JM; Chabner BA
    Cancer Res; 1980 Jun; 40(6):1902-6. PubMed ID: 7371023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemical modification of anticancer agents from viewpoints of their pharmacokinetics].
    Fujita H
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):733-40. PubMed ID: 6424579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
    Machover D
    Bull Cancer; 1994 Dec; 81 Suppl 2():74s-77s. PubMed ID: 7727863
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose-dependent metabolism, therapeutic effect, and toxicity of anticancer drugs in man.
    Powis G
    Drug Metab Rev; 1983; 14(6):1145-63. PubMed ID: 6373208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. m-AMSA and PALA: two new agents in cancer chemotherapy.
    Rozencweig M; Von Hoff DD; Cysyk RL; Muggia FM
    Cancer Chemother Pharmacol; 1979; 3(3):135-41. PubMed ID: 393427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological monitoring screening of patients provided antineoplastic drugs including adriamycin, cyclophosphamide, 5-fluorouracil, methotrexate, and vincristine.
    Newman MA; Hee SQ; Schoeny R; Lowry L
    Cancer Res; 1990 Jun; 50(11):3351-66. PubMed ID: 2334930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.